SLF2: A Non-Coding RNA Molecule as A Potential Drug Target (G55719)

Target Name: SLF2

NCBI ID: G55719

SLF2

SLF2: A Non-Coding RNA Molecule as A Potential Drug Target

SLF2 (Smc5/6 localization factor 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SLF2 is a key regulator of gene expression and has been shown to play a role in a variety of cellular processes, including cell adhesion, migration, and invasion.

SLF2 is a member of the SLF2 family, which includes several similar non-coding RNAs that are involved in the regulation of gene expression. These non-coding RNAs are known as SLF2-like molecules and are characterized by the presence of a specific stem-loop structure.

SLF2 has been shown to play a role in the regulation of gene expression in a variety of organisms, including humans. For example, studies have shown that SLF2 is involved in the regulation of gene expression in cancer cells, where it has been shown to promote the growth and survival of these cells.

In addition to its role in gene expression, SLF2 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that SLF2 is involved in the regulation of cell migration and invasion, which are important processes that contribute to the development of cancer.

The potential drug target status of SLF2 is based on several factors. First, SLF2 has been shown to be involved in the regulation of gene expression, which is a key step in the development of many diseases, including cancer. Second, SLF2 has been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer.

Third, SLF2 has been shown to be a good candidate for a drug target because it is relatively stable and has a low level of expression in many tissues, which makes it less likely to be a difficult target for drugs.

Finally, SLF2 has been shown to be a good candidate for a drug target because it is involved in a variety of cellular processes that are important for the development and progression of cancer, which makes it a potential target for drugs that can inhibit its activity.

In conclusion, SLF2 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and the regulation of cellular processes that are important for the development and progression of cancer. Its potential drug target status is based on its involvement in these processes and its relatively stable and low level of expression in many tissues. Further research is needed to fully understand the role of SLF2 in the development and progression of cancer and to identify potential drugs that can inhibit its activity.

Protein Name: SMC5-SMC6 Complex Localization Factor 2

Functions: Plays a role in the DNA damage response (DDR) pathway by regulating postreplication repair of UV-damaged DNA and genomic stability maintenance (PubMed:25931565). The SLF1-SLF2 complex acts to link RAD18 with the SMC5-SMC6 complex at replication-coupled interstrand cross-links (ICL) and DNA double-strand breaks (DSBs) sites on chromatin during DNA repair in response to stalled replication forks (PubMed:25931565). Promotes the recruitment of the SMC5-SMC6 complex to DNA lesions (PubMed:25931565)

The "SLF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets